FDA
-
-
-
-
-
-
-
Nuvation Bio posts $31.7M Q2 revenue, widens net loss to $62.8M
-
-
-
-
-
-
-
Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting
-
-
-
-
-
-
-
Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026
-
-
-
-
-
-
-
Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026
-
-
-
-
-
-
-
Nuvation Bio partners with Eisai for taletrectinib in Europe
-
-
-
-
-
-
-
Nuvation Bio begins phase 3 trial of safusidenib for brain cancer
-
-
-
-
-
-
-
RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'
-
331,677 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

